Infliximab-induced interstitial lung disease

被引:6
作者
Karampitsakos, Theodoros [1 ]
Papaioannou, Ourania [1 ]
Sampsonas, Fotios [1 ]
Tzouvelekis, Argyrios [1 ]
机构
[1] Univ Hosp Patras, Dept Resp Med, Patras, Greece
关键词
interstitial lung disease; drugs; respiratory system; biological agents; IDIOPATHIC PULMONARY-FIBROSIS; SARCOIDOSIS; UPDATE; FACTS;
D O I
10.1136/bcr-2021-245726
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 70-year-old man was referred to our respiratory department with non-productive cough over the past 6 months. High-resolution CT revealed reticular pattern with basal and peripheral predominance, centrilobular nodules and mild ground glass opacities. Serology tests were normal and bronchoalveolar lavage revealed lymphocytosis. Pulmonary function tests showed functional impairment and reduced diffusing capacity for carbon monoxide. Meticulous evaluation of patient's medical history unveiled longitudinal administration of infliximab due to diagnosis of psoriasis. The working diagnosis of drug-induced interstitial lung disease was proposed following multidisciplinary discussion. Considerable radiological and functional improvement was determined 6 months following infliximab discontinuation without implementation of corticosteroids. To this end, the patient has reported remission of cough and functional improvement.
引用
收藏
页数:3
相关论文
共 24 条
[1]   Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis [J].
Atzeni, Fabiola ;
Boiardi, Luigi ;
Salli, Salvatore ;
Benucci, Maurizio ;
Sarzi-Puttini, Piercarlo .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2013, 9 (07) :649-657
[2]   Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement [J].
Baughman, Robert P. ;
Drent, Marjolein ;
Kavuru, Mani ;
Judson, Marc A. ;
Costabel, Ulrich ;
du Bois, Roland ;
Albera, Carlo ;
Brutsche, Martin ;
Davis, Gerald ;
Donohue, James F. ;
Mueller-Quernheim, Joachim ;
Schlenker-Herceg, Rozsa ;
Flavin, Susan ;
Lo, Kim Hung ;
Oemar, Barry ;
Barnathan, Elliot S. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 174 (07) :795-802
[3]   New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches [J].
Baughman, Robert P. ;
Grutters, Jan C. .
LANCET RESPIRATORY MEDICINE, 2015, 3 (10) :813-822
[4]   Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies [J].
Chen, Juan ;
Chi, Shuhong ;
Li, Feng ;
Yang, Jiali ;
Cho, William C. ;
Liu, Xiaoming .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (03) :265-283
[5]   A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis [J].
Glaspole, Ian N. ;
Hoy, Ryan F. ;
Ryan, Peter F. .
RHEUMATOLOGY, 2013, 52 (12) :2302-2304
[6]   Respiratory failure due to infliximab induced interstitial lung disease [J].
Kakavas, Sotiris ;
Balis, Evangelos ;
Lazarou, Vasiliki ;
Kouvela, Marousa ;
Tatsis, Georgios .
HEART & LUNG, 2013, 42 (06) :480-482
[7]   Biologic Treatments in Interstitial Lung Diseases [J].
Karampitsakos, Theodoros ;
Vraka, Argyro ;
Bouros, Demosthenes ;
Liossis, Stamatis-Nick ;
Tzouvelekis, Argyris .
FRONTIERS IN MEDICINE, 2019, 6
[8]   Clinical pharmacokinetics and use of infliximab [J].
Klotz, Ulrich ;
Teml, Alexander ;
Schwab, Matthias .
CLINICAL PHARMACOKINETICS, 2007, 46 (08) :645-660
[9]   The risk of interstitial lung disease during biological treatment in Japanese patients with psoriasis [J].
Matsumoto, Y. ;
Abe, N. ;
Tobita, R. ;
Kawakami, H. ;
Nakayama, H. ;
Setoguchi, Y. ;
Tsuboi, R. ;
Okubo, Y. .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2020, 45 (07) :853-858
[10]   Biological treatments and connective tissue disease associated interstitial lung disease [J].
Panopoulos, Stylianos T. ;
Sfikakis, Petros P. .
CURRENT OPINION IN PULMONARY MEDICINE, 2011, 17 (05) :362-367